Trial Profile
Retrospective Study to Determinate the Clinical Phenotype of Patients With Non Squamous NSCLC Treated With First Line Bevacizumab-based Therapy That Reached a Long PFS.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Roche
- 23 May 2013 Actual initiation date changed from May 2012 to Dec 2011 as reported by ClinicalTrials.gov.
- 01 May 2012 Actual end date May 2012 added as reported by ClinicalTrials.gov.
- 01 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.